Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) - (Optimizing Acute Stress Reaction Interventions With TNX-102 SL - OASIS)

This study will examine the safety and efficacy of TNX-102 SL to reduce ASR symptoms and behavioral changes among patients presenting to the emergency department (ED) after motor vehicle collision (MVC). Specifically, the investigators will perform the Optimizing Acute Stress reaction Interventions with TNX-102 SL (OASIS) Trial, a double-blind placebo-controlled randomized clinical trial (RCT) to determine if TNX-102 SL initiated in the ED in the hours after MVC to high risk individuals, treats/reduces acute stress reaction (ASR)/acute stress disorder (ASD) symptoms (primary outcome), improves neurocognitive function, and prevents/reduces posttraumatic stress (PTS) symptoms (secondary outcomes) long term. 180 participants will be randomized, receive study drug in ED and be discharged with a 2-week drug supply. Prior to initial dose of study drug administration, and during the hours, days, and weeks after participants will receive serial longitudinal assessments of psychological and somatic symptoms, neurocognitive function, and adverse events.

开始日期2025-03-25

申办/合作机构

The University of North Carolina at Chapel Hill

[+3]

NCT06462781

/ Not yet recruiting临床2期IIT

Intra-Arterial Injection of Lidocaine and Glucocorticoid in the Treatment of Intractable Headaches

The goal of this clinical trial is to test whether injecting lidocaine and steroids into two blood vessels of the brain can help treat chronic headaches (migraines).
The main questions this study aims to answer are:
* Is this treatment safe for chronic migraine patients?
* Is this treatment effective for chronic migraine patients?
Participants will:
* Be treated once with lidocaine and steroid infused into the middle meningeal arteries (two blood vessels in the brain).
* Attend appointments scheduled 1 week, 6 weeks, and 12 weeks after the treatment for a checkup.
* Keep a log of their symptoms.

开始日期2025-03-01

申办/合作机构

The Cooper Health System, Inc.

NCT06289985

/ RecruitingN/AIIT

STEP: StrokeNet Thrombectomy Endovascular Platform

STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).

开始日期2025-01-31

申办/合作机构

The Medical University of South Carolina

[+9]

100 项与 The Cooper Health System, Inc. 相关的临床结果

登录后查看更多信息

0 项与 The Cooper Health System, Inc. 相关的专利（医药）

登录后查看更多信息

1,645

项与 The Cooper Health System, Inc. 相关的文献（医药）

2025-08-01·JOURNAL OF CRITICAL CARE

ICU-acquired weakness: Critical illness myopathy and polyneuropathy

Review

作者: Weber, Harli ; Huang, Audrey ; Gozum, Nimrod ; Henson, Theresa ; Yang, Jenny ; Mayer, Stephan A ; Badjatia, Neeraj ; Salazar, Marco ; Harrison, Taylor B

Critical illness myopathy (CIM) and critical illness polyneuropathy (CIP) are significant complications in intensive care unit (ICU) patients, first identified in the late 20th century. These conditions often present as flaccid paralysis and respiratory muscle weakness, making it challenging for patients to wean off ventilatory support. The incidence of ICU-acquired weakness, which includes CIM and CIP, ranges from 25 % to 84 % among long-term ventilated patients, with higher rates observed in those with sepsis or systemic inflammatory response syndrome. CIM is characterized by muscle wasting and can be confirmed using electromyography and muscle biopsy. The pathogenesis of CIM involves the loss of thick myosin filaments, while the proposed etiology of CIP centers around increased permeability of nerve axons, leading to axonal degeneration. Risk factors for developing these conditions include prolonged ICU length of stay, sepsis, multi-system organ dysfunction, hyperglycemia, as well as exposure to steroids and neuromuscular blocking agents. Emerging diagnostic tools including muscle ultrasound, magnetic resonance imaging (MRI), and biomarkers such as interleukin-6 (IL-6) and growth differentiation factor-15 (GDF-15) show promise in early detection and differentiation of CIM and CIP. Preventative and therapeutic treatment focuses on early mobilization, minimizing sedation, optimizing nutritional support, and use of intensive insulin therapy to prevent prolonged hyperglycemia. Despite these advancements, CIM and CIP continue to pose significant challenges, emphasizing the need for ongoing research to improve patient outcomes and develop effective treatments.

2025-07-01·JOURNAL OF SURGICAL RESEARCH

Tourniquet in Place as Full Trauma Team Activation Criterion Maintains an Acceptable Overtriage Rate

Article

作者: Desmond, Khor ; Benjamin, Martinez ; Kelsey, Alabaster ; Grace, Chang ; Heather M, Grossman Verner ; Warren, Dorlac ; Alison, Wilson ; Linda, Zier ; John G, Myers ; AlleaBelle, Gongola ; Claire, Hardman ; Mark, Lieser ; Peter E, Fischer ; Reza, Askari ; Zachery E, Stillman ; Lawrence, Lottenberg ; Merry, Peckham ; Mae, Lindner ; Robert D, Fullerton ; Erik J, Teicher ; Pedro, Teixeira ; Todd W, Costantini ; James M, Haan ; George, Singer ; Jinfeng, Han ; Amy, Brown ; Douglas R, Fraser ; Juan, Duchesne ; Michael S, Truitt ; Peter, Ekeh ; Allison G, McNickle ; Henrik O, Berdel ; Laura N, Godat ; Catherine G, Velopoulos ; Danielle, Tatum ; Rebecca, Schroll ; Thomas J, Schroeppel ; Andrew, Pop ; James, Bardes ; Barbara, Okafor ; Rob, Todd S ; Toby M, Enniss ; Kelly L, Lightwine ; Alison, Smith ; Kenji, Inaba ; Dennis Y, Kim ; Anthony J, Bottiggi ; Kennith, Coleman ; Elena, Lita ; David, Turay ; Robert C, Mabe ; Paula, Ferrada ; Christopher, Brown ; Marquinn, Duke ; Shane, Urban

INTRODUCTION:

Prehospital tourniquet placement is not a required criterion for standard trauma team activation (TTA-S) as recommended by the American College of Surgeons Committee on Trauma. Educational campaigns such as STOP THE BLEED have led to an increase in tourniquet applications in the prehospital setting. We intend to evaluate if using extended trauma team activation (TTA-T) criteria, which includes tourniquet application, would lead to an acceptable amount of overtriage.

METHODS:

This was a multicenter retrospective analysis, utilizing the American Association for the Surgery of Trauma Major Extremity Trauma Tourniquet Database, comparing the overtriage rate of TTA-S criteria against the TTA-T criteria.

RESULTS:

A total of 1235 patients were included, with 687 meeting the TTA-S criteria and an additional 175 patients meeting the TTA-T criteria. The overtriage rate was calculated to be 21.2%, within the accepted over triage rate of 25%-35%.

CONCLUSIONS:

Field tourniquet application for life-threatening hemorrhage, although not an American College of Surgeons Committee on Trauma criterion for TTA, should be considered for full TTA. Utilizing this as a criterion for TTA is associated with an acceptable rate of overtriage, while also having the benefit of rapid surgical team evaluation and intervention for possible life- or limb-threatening injuries.

2025-06-01·Translational stroke research

Development of a 3D Brain Model to Study Sex-Specific Neuroinflammation After Hemorrhagic Stroke

Article

作者: Choudhary, Hadi Hasan ; Zhang, Feng ; Hanafy, Khalid A ; Mehta, Hritik ; Jovin, Tudor G ; Islam, Rezwanul

Abstract:

Subarachnoid hemorrhage (SAH) accounts for 5% of stroke, with women having a decreased inflammatory response compared to men; however, this mechanism has yet to be identified. One hurdle in SAH research is the lack of human brain models. Studies in murine models are helpful, but human models should be used in conjunction for improved translatability. These observations lead us to develop a 3D system to study the sex-specific microglial and neuroglial function in a novel in vitro human SAH model and compare it to our validated in vivo SAH model. Our lab has developed a 3D, membrane-based in vitro cell culture system with human astrocytes, microglia, and neurons from both sexes. The 3D cultures were incubated with male and female cerebrospinal fluid from SAH patients in the Neuro-ICU. Furthermore, microglial morphology, erythrophagocytosis, microglial inflammatory cytokine production, and neuronal apoptosis were studied and compared with our murine SAH models. The human 3D system demonstrated intercellular interactions and proportions of the three cell types similar to the adult human brain. In vitro and in vivo models of SAH showed concordance in male microglia being more inflammatory than females via morphology and flow cytometry. On the contrary, both in vitro and in vivo models revealed that female microglia were more phagocytic and less prone to damaging neurons than males. One possible explanation for the increased phagocytic ability of female microglia was the increased expression of CD206 and MerTK. Our in vitro, human, 3D cell culture SAH model showed similar results to our in vivo murine SAH model with respect to microglial morphology, inflammation, and phagocytosis when comparing the sexes. A human 3D brain model of SAH may be a useful adjunct to murine models to improve translation to SAH patients.

项与 The Cooper Health System, Inc. 相关的新闻（医药）

2024-07-01

·SYNAPSE

It’s Official: Cape Regional Is Now Part of Cooper University Health Care

The closing is complete and Cape Regional Health System is now part of Cooper University Health Care, effective today, July 1, 2024. As part of the closing, Cape Regional Medical Center has been renamed Cooper University Hospital Cape Regional. "This agreement will transform health care for the residents and visitors of Cape May and Atlantic counties,” said George E. Norcross III, Chairman of Cooper University Health Care’s Board of Trustees. “We are ready to move forward and for our unified team to begin delivering the highest level of advanced health care to more people in shore communities and beyond. We are excited by the opportunity to build something extraordinary here.” “Today is a significant day and a new chapter for health care in Cape May County and beyond. I want to thank our entire team for all the great work in serving the people of this community so well, for so many years, that brought us to this exciting new beginning where we will be able to serve even more people,” stated Garry Gilbert, former Chairman, Cape Regional Health System Board of Trustees. In December 2022, Cooper and Cape Regional announced the proposal to join together, followed by execution of a Definitive Agreement in April 2023. Final regulatory approval by the New Jersey Superior Court of Cape May County was secured on May 28, 2024. The transaction was officially completed effective today. Cooper, with its market-leading MD Anderson Cancer Center at Cooper, is based in the City of Camden and is southern New Jersey’s leading academic health system and only Level I trauma center, with more than $2.2 billion in revenue. Cape Regional Health System has earned the Gold Seal of Approval from the Joint Commission and is an integrated health care delivery system serving residents throughout Cape May County. “We are happy to have brought this vision to reality. We look forward to working with our new colleagues to build upon their tremendous work and provide the highest quality of primary and specialty care to the residents and visitors at the shore,” said Anthony J. Mazzarelli, MD, JD, MBE, co-CEO of Cooper University Health Care. “Today is a day of great promise, as two teams have become one team dedicated to serving communities across South Jersey,” said Kevin O’Dowd, JD, co-CEO of Cooper University Health Care. “We look forward to the future and the work we will do with our new team members and with residents and visitors to the shore region.” “The future of health care is very bright for the residents and visitors of Cape May County as a result of this merger,” stated Joanne Carrocino, FACHE, CEO, Cooper University Hospital Cape Regional. “The Cape Regional team is excited to begin working with our new colleagues at Cooper.” “The entire Cooper team is looking forward to collaborating with our new team members in Cape May County to enhance access to the highest levels of care and enrich the health care experience for the people of Cape May and Atlantic counties,” said Christine Winn, PhD, FACHE, Senior Vice President and Chief Regional Officer for Cooper, who will oversee Cooper operations in Cape May and Atlantic counties, including Cooper University Hospital Cape Regional.

并购

2022-12-13

·SYNAPSE

Cooper University Health Care and Cape Regional Health System to Join Forces to Expand Services to Jersey Shore Residents and Visitors

(CAMDEN and CAPE MAY, NJ) – Cooper University Health Care and Cape Regional Health System announced that the two systems have signed a Letter of Intent to merge. When complete, this historic partnership will bring together two respected health systems to expand access to specialty health services to residents and visitors of Cape May County. “For more than 135 years, Cooper has continued to expand its reach to provide advanced health care to the people of South Jersey,” said George E. Norcross, III, Chairman of Cooper University Health Care’s Board of Trustees. “This merger of two trusted health care organizations will benefit tens of thousands of residents and visitors to Cape May County and strengthen the overall health care system in South Jersey.” “As it becomes more and more challenging for smaller health systems to operate independently, merging with Cooper made the most sense as we share the same commitment to the communities we serve and to providing the highest quality care to our patients,” stated Garry Gilbert, Chairman, Cape Regional Health System Board of Trustees. “Cape Regional and Cooper have had a strong working relationship for many years as Cooper has staffed our Intensive Care Unit with fellowship-trained Intensivist physicians as well as provided tele-ICU, tele-stroke, and tele-neurology services that have truly enhanced the quality of care for our community,” said Joanne Carrocino, President & CEO of Cape Regional Health System. Cooper, with its market leading MD Anderson Cancer Center at Cooper, is based in the City of Camden and is southern New Jersey’s only academic health system and Level I trauma center with $2 billion in revenue. Cape Regional Health System has earned the Gold Seal of Approval from the Joint Commission and is an integrated healthcare delivery system serving the residents throughout Cape May County. “Cooper is incredibly honored to be given an opportunity to partner with the nearly 1,500 Cape Regional team members who have built a distinguished health system of high-quality clinical outcomes and commitment to their community,” said Kevin O’Dowd, co-CEO of Cooper. “We look forward to working with our future colleagues at Cape Regional to build upon this tremendous legacy of service to residents of the Cape May region.” The combined health system will have: “By expanding our current working relationship with the Cape Regional team, we will be able to bring additional advanced cancer and specialty health care services to local residents close to where they live,” said Dr. Anthony Mazzarelli, co-CEO of Cooper. The signing of the Letter of Intent is the first step in a lengthy process. Cooper and Cape Regional will be working toward signing a Definitive Agreement in March 2023. Thereafter, the health systems will seek regulatory approval for the merger, which could take until the first quarter of 2024.

并购

100 项与 The Cooper Health System, Inc. 相关的药物交易

登录后查看更多信息

100 项与 The Cooper Health System, Inc. 相关的转化医学

登录后查看更多信息